Ischemic Heart Disease
Conditions
Brief summary
Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.
Detailed description
The investigators hypothesized that short-term (1-3 months) DAPT followed by clopidogrel monotherapy will be superior to short-term DAPT followed by aspirin monotherapy after PCI in patients with ischemic heart disease. We will evaluate whether clopidogrel monotherapy will reduce the rate of net adverse clinical events (NACE) at 12 months compared to aspirin monotherapy after very-short term DAPT. Eligible patients will be randomized to short-term DAPT followed by clopidogrel monotherapy or short-term DAPT followed by aspirin monotherapy at hospitalization for index PCI. Randomization will be stratified according to 1) bleeding risk (high bleeding risk \[HBR\] or non-HBR), 2) clinical presentation (acute coronary syndrome or chronic coronary artery disease), and 3) lesion complexity (non-complex or complex lesion). Regarding the duration of very-short term DAPT, the maintenance duration of DAPT (1-month or 3-month) will be determined as follows: * If the patients are at HBR (HBR is defined according to ARC-HBR criteria: meeting at least 1 major or 2 minor criteria), 1-month DAPT will be given regardless of clinical presentation or lesion complexity. * In the patients are at non-HBR, 3-month DAPT will be given in those treated for unstable angina and/or complex lesions (complex lesion is defined as meeting at least one of the following: number of stents implanted ≥3, number of lesions treated ≥3, 3-vessel treated, bifurcation PCI with 2 stents, total stent length ≥60mm, or chronic total occlusion).
Interventions
Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
DEVICEzotarolimus-eluting stent (Resolute Onyx ®)
zotarolimus-eluting stent (Resolute Onyx ®)
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 84 Years
Healthy volunteers
No
Inclusion criteria
1. Patients ≥19 years 2. Patients who received new generation zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease 3. Provision of informed consent
Exclusion criteria
1. Age ≥ 85 years 2. Acute myocardial infarction 2\. Left main bifurcation requiring 2-stent technique 3. Pregnant women or women with potential childbearing 4. Life expectancy \< 1 year 5. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 6. Inability to understand or read the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Net adverse clinical events (NACE) | 1 year after the procedure | Composite of all-cause death, myocardial infarction, stroke, or major bleeding (BARC 2, 3 or 5) |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse cardiac and cerebrovascular events (MACCE: composite of all-cause death, myocardial infarction, or stroke) | 1 year after the procedure |
| Cardiac death | 1 year after the procedure |
| Each component of NACE | 1 year after the procedure |
| Target-vessel revascularization | 1 year after the procedure |
| Target-lesion revascularization | 1 year after the procedure |
| Stent thrombosis (definite or probable) | 1 year after the procedure |
Countries
South Korea
Contacts
Primary ContactByeong-Keuk Kim
Outcome results
None listed